208 related articles for article (PubMed ID: 29907543)
21. [Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].
Rasche L; Einsele H; Nitschmann S
Internist (Berl); 2019 Jun; 60(6):658-660. PubMed ID: 30941437
[No Abstract] [Full Text] [Related]
22. Thalidomide-induced fulminant hepatic failure.
Hamadani M; Benson DM; Copelan EA
Mayo Clin Proc; 2007 May; 82(5):638. PubMed ID: 17493431
[No Abstract] [Full Text] [Related]
23. Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
Conticello C; Parisi M; Romano A; Calafiore V; Ancora F; La Fauci A; Consoli ML; Di Raimondo F
Future Oncol; 2017 Feb; 13(5s):3-6. PubMed ID: 28116941
[TBL] [Abstract][Full Text] [Related]
24. Effective treatment of pomalidomide in central nervous system myelomatosis.
Mussetti A; Dalto S; Montefusco V
Leuk Lymphoma; 2013 Apr; 54(4):864-6. PubMed ID: 22880953
[No Abstract] [Full Text] [Related]
25. Pomalidomide approved for multiple myeloma.
Traynor K
Am J Health Syst Pharm; 2013 Mar; 70(6):474. PubMed ID: 23456394
[No Abstract] [Full Text] [Related]
26. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
Charlinski G; Grzasko N; Jurczyszyn A; Janczarski M; Szeremet A; Waszczuk-Gajda A; Bernatowicz P; Swiderska A; Guzicka-Kazimierczak R; Lech-Maranda E; Szczepaniak A; Wichary R; Dmoszynska A
Eur J Haematol; 2018 Sep; 101(3):354-361. PubMed ID: 29882602
[TBL] [Abstract][Full Text] [Related]
27. Successful detoxification and liver transplantation in a severe poisoning with a chemical wood preservative containing chromium, copper, and arsenic.
Breuer C; Oh J; Nolkemper D; Achilles EG; Fischer L; Eglite I; Guesmer C; Heitland P; Koester HD; Brinkert F; Singer D; Blohm M
Transplantation; 2015 Apr; 99(4):e29-30. PubMed ID: 25827325
[No Abstract] [Full Text] [Related]
28. Ecstasy induced fatal hepatic failure.
Colak Y; Tuncer I; Enc FY; Ozturk O; Kiziltas S; Ulasoglu C
J Gastrointestin Liver Dis; 2011 Jun; 20(2):215-6. PubMed ID: 21725523
[No Abstract] [Full Text] [Related]
29. Propylthiouracil-induced hepatotoxicity.
Hardee JT; Barnett AL; Thannoun A; Eghtesad B; Wheeler D; Jamal MM
West J Med; 1996 Sep; 165(3):144-7. PubMed ID: 8909171
[No Abstract] [Full Text] [Related]
30. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
Nakamura N; Kanemura N; Shibata Y; Matsumoto T; Mabuchi R; Nakamura H; Kitagawa J; Goto N; Hara T; Tsurumi H; Moriwaki H
Leuk Lymphoma; 2014 Jul; 55(7):1691-3. PubMed ID: 24138307
[No Abstract] [Full Text] [Related]
31. [It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy].
Takamatsu Y
Rinsho Ketsueki; 2012 Jun; 53(6):587-93. PubMed ID: 22790633
[No Abstract] [Full Text] [Related]
32. Pomalidomide in the management of relapsed multiple myeloma.
Touzeau C; Moreau P
Future Oncol; 2016 Sep; 12(17):1975-83. PubMed ID: 27283457
[TBL] [Abstract][Full Text] [Related]
33. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Highsmith KN; Chen SE; Horowitz S
Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
[TBL] [Abstract][Full Text] [Related]
34. Acute Liver Failure Due to Etodolac, a Selective Cycloxygenase- 2 (COX -2) Inhibitor Non-Steroidal Anti-Inflammatory Drug Established by RUCAM-Based Causality Assessment.
Taneja S; Kumar P; Rathi S; Duseja A; Singh V; Dhiman RK; Chawla YK
Ann Hepatol; 2017; 16(5):818-821. PubMed ID: 28809737
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide in multiple myeloma: Current status and future potential.
Quach H; Kalff A; Spencer A
Am J Hematol; 2012 Dec; 87(12):1089-95. PubMed ID: 22641420
[TBL] [Abstract][Full Text] [Related]
36. Pomalidomide for patients with multiple myeloma.
Gras J
Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
[TBL] [Abstract][Full Text] [Related]
37. Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma.
Trojan A; Chasse E; Gay B; Pichert G; Taverna C
Ann Oncol; 2003 Mar; 14(3):501-2. PubMed ID: 12598363
[No Abstract] [Full Text] [Related]
38. How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide.
Kastritis E; Dimopoulos M
Leuk Lymphoma; 2007 Dec; 48(12):2295-7. PubMed ID: 18066998
[No Abstract] [Full Text] [Related]
39. Impact of pomalidomide therapy in multiple myeloma: a recent survey.
Kumar A; Porwal M; Verma A; Mishra AK
J Chemother; 2014 Dec; 26(6):321-7. PubMed ID: 25004945
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide-induced acute liver failure.
Jain P
Blood Transfus; 2009 Oct; 7(4):335-6; author reply 337. PubMed ID: 20011646
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
